Laxoberon

Sodium Picosulfate

Method of action: Laxative

Treatment option: Constipation, Proctitis

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Laxoberon

Property	Description
Active Ingredient	Sodium Picosulfate
Form	Oral Solution, Coated Tablets
Pharmacological Class	Stimulant Laxative, Contact Laxative
Common Use	Relief of Acute and Chronic Constipation
Origin	Synthetic Pro-drug (Triaryl Methane Derivative)

What Type of Medicine is Laxoberon and Its Identity?

Laxoberon is a pharmaceutical preparation classified as a stimulant laxative and contact laxative, primarily used for the symptomatic relief of functional constipation. The active component is the synthetic chemical entity, Sodium Picosulfate (INN), which defines its function as a monocomponent product intended for oral administration. Sodium Picosulfate functions as an agent that increases the movement of the gut. This confirms the medicine works by promoting the necessary motion for stool passage.

The substance is uniquely classified as a pro-drug, meaning it is initially inert and requires a metabolic conversion to become effective. The active form is generated specifically within the large intestine, or colon, after interacting with the natural resident colonic bacteria. This mechanism, and the subsequent release of the active metabolite, Bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), delivers a targeted, local effect with minimal systemic absorption.

General Purpose and Unique Forms of Laxoberon

The general therapeutic purpose of this medicine is to provide effective bowel evacuation and relief from both acute and chronic constipation. This benefit is achieved through a dual physiological action that is highly localized to the colon. The active metabolite acts directly to promote stimulation of peristalsis (muscle movement) and influences the transport of water and electrolytes to ensure effective hydration support. This means the medicine ensures both the propulsion and the necessary softening of the stool to ease the process.

Laxoberon is frequently recognized for offering both an Oral Solution (drops) and Coated Tablets, a differentiating factor that allows flexible options for different patient groups, including children or individuals who struggle to swallow pills. The Oral Solution provides an easy-to-measure liquid form, which is a key positioning element compared to tablet-only alternatives.

What side effects are possible with Laxoberon?

Possible side effects and safety information

Adverse reactions to Sodium Picosulfate are classified in regulatory documents according to frequency and the body system affected. The official safety profile focuses on potential gastrointestinal and nervous system effects, as well as specific risks associated with long-term exposure.

Official Adverse Reaction Classification

System-Organ Class	Common Adverse Reactions	Uncommon Adverse Reactions
Gastrointestinal Disorders	Abdominal pain, Abdominal cramps	Diarrhea, Vomiting, Nausea
Nervous System Disorders	Headache	Dizziness
Skin/Immune Disorders	—	Hypersensitivity reactions, Rash

Serious Adverse Reactions and Safety Patterns

Official labeling documents note that certain reactions, while generally classified as Not Known in frequency, are considered clinically significant. These include seizures, syncope (fainting), and severe anaphylactic reactions. Many of the serious effects, particularly the nervous system disorders, are often associated with the secondary development of severe fluid and electrolyte imbalance, which is a key documented safety concern.

Regulatory safety notes emphasize that the risk of fluid and electrolyte imbalance is specifically associated with the long-term and excessive use of the medicine. Furthermore, co-administration with other medicines, such as diuretics or corticosteroids, may increase this risk. The medicine is formally contraindicated in patients presenting with acute abdominal conditions (e.g., appendicitis), intestinal obstruction, or existing severe dehydration, establishing a defined boundary for its use.

Overdose and Emergency Response

Overdose Manifestations

Overdosage of Sodium Picosulfate (the active ingredient in Laxoberon), whether from a high single dose or prolonged excessive use, is officially documented to result in specific clinical consequences. The immediate manifestations include severe diarrhoea and intense abdominal cramps or abdominal pain.

Overdose also leads to a clinically significant loss of electrolytes, notably potassium, which can cause hypokalaemia, muscle weakness, and increase the risk of adverse effects from other medicines like cardiac glycosides. Chronic abuse is associated with further severe outcomes, including renal tubular damage, secondary hyperaldosteronism, and colonic mucosal ischaemia.

When to Seek Urgent Medical Help

Official regulatory information requires specific actions in the event of suspected overdose:

Contact a poison control center or emergency room at once if an overdose is suspected, or if severe symptoms such as prolonged diarrhoea, significant abdominal pain, or signs of dehydration occur.
You should also consult with a doctor or pharmacist immediately if you have accidentally taken too much of this medicine.

Supportive Management

There is no specific antidote documented for this medicine. Management, as described in regulatory labels, is supportive, focusing on the replacement of lost fluids and correction of electrolyte imbalance. This supportive action is especially important in the elderly and the young due to their increased vulnerability to fluid loss.

Therapeutic Uses of Laxoberon

What Laxoberon Treats: Main Uses and Benefits

Laxoberon is commonly used to help with short-term relief from symptoms related to physical discomfort, and may be part of symptomatic management for constipation. Its active ingredient, sodium picosulfate, belongs to a therapeutic class relevant in contexts marked by increased discomfort or tension. This type of symptomatic support is applied across domains where additional management of discomfort is required.

Addressing Acute Symptom Discomfort

The medication helps address symptom clusters that may become intense or disruptive, specifically managing symptoms that interfere with daily functioning. This supportive role makes it relevant when supportive symptom management is appropriate for conditions characterized by periods of heightened symptoms.

Supporting Functional Stability

Laxoberon contributes to improved comfort during periods of heightened symptoms, and may assist with functional stability. It supports the patient during difficult episodes by easing distress, providing support that helps ease the overall symptom burden.

Quick Fact: Relief for Infrequent Bowel Movements

Regulatory References

MHRA Public Assessment Report on stimulant laxatives

Eligibility and Restrictions for Use

This section summarizes the official eligibility and non-eligibility rules for Laxoberon, strictly based on regulatory documentation.

Populations Who Must Not Use Laxoberon (Contraindications)

Use of the medicine is formally prohibited for individuals with certain acute and severe conditions, as established in official labeling. These include:

Acute Abdominal Conditions: Patients experiencing intestinal obstruction (ileus), acute surgical abdominal conditions (such as appendicitis), or acute inflammatory bowel diseases.
Hypersensitivity: Individuals with a known allergy or hypersensitivity to the active ingredient, Sodium Picosulfate, or any other component of the formulation.
Metabolic/Fluid Status: Patients suffering from severe dehydration or with rare hereditary problems of fructose intolerance.

Age and Special Considerations

Official documents define specific limits and restrictions regarding age and physiological state:

Age Restriction: The medicine should not be taken by children under 10 years of age without explicit medical advice. For some formulations, use is contraindicated in children below 4 years of age.
Pregnancy and Lactation: Use during pregnancy, especially the first trimester, and while breastfeeding is generally not recommended, except when medically advised after weighing potential risks.
Duration of Use: The medicine is not intended for continuous daily use or prolonged periods without investigation and supervision by a healthcare professional.

What should I know about interactions with other medicines?

Laxoberon Interactions with other medicines and products

Official regulatory information for Sodium Picosulfate identifies specific drug interaction patterns concerning electrolyte balance, absorption, and efficacy, based on pharmacodynamic and gastrointestinal transit effects.

Pharmacodynamic and Electrolyte Risk

Co-administration with diuretics or adrenocorticosteroids may increase the risk of electrolyte imbalance, specifically hypokalemia, particularly if the laxative is used in excessive doses. This imbalance can lead to increased sensitivity to cardiac glycosides (e.g., Digoxin), a documented interaction requiring caution.

Efficacy and Absorption Constraints

The laxative action may be reduced if the product is taken concurrently with broad-spectrum antibiotics. This is attributed to the antibiotics interfering with the necessary colonic bacteria that convert the pro-drug into its active form. For combination products, the accelerated gut transit time may cause incomplete absorption of other oral medications. Therefore, specific time separation rules are mandated for general oral medicines and extended separation (up to six hours) for certain high-risk drugs, including specific antibiotics and iron supplements.

Regulatory and Population-Specific Notes

Official labeling for related combination products dictates that patients not drink alcohol during treatment. Furthermore, severe renal impairment constitutes a formal contraindication for the combination product due to the risk of magnesium accumulation, which is a population-specific interaction concern documented by regulatory authorities.

Mechanism of Action

Pro-drug Activation and Localized Delivery

Laxoberon's active ingredient, Sodium Picosulfate, is a pro-drug that is biologically inert upon ingestion. It relies on the colonic bacteria (microflora) to perform a necessary hydrolysis reaction that releases the active metabolite, Bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM). This transformation mechanism ensures that the drug's activity is precisely restricted to the colon.

Dual Mechanism: Motility and Fluid Modulation

Once released, BHPM engages two critical mechanistic domains simultaneously. First, it stimulates enteric neurons in the gut wall, accelerating coordinated muscle contractions known as peristalsis. Second, it modulates colonocytes (lining cells), inhibiting water and electrolyte absorption while promoting their secretion into the lumen.

Resulting Physiological Effect

The accelerated peristalsis generates propulsive force, while the enhanced fluid secretion softens and bulks the colonic contents. These two actions collectively initiate the process of bowel content expulsion. This dual physiological action dictates the functional characteristics of the mechanism in initiating the expulsion of contents.

Dosage and Administration Information

How to Use Laxoberon

Laxoberon (sodium picosulfate) is used according to specific administration guidelines for the symptomatic relief of constipation.

Administration Scope

Feature	General Instructions
Route of Administration	Oral administration only.
Dosing Schedule	Adults and children over 10 years: Range is 5 mg to 10 mg once daily. Starting with the lowest effective dose is recommended.
Timing	Administered at night/bedtime to produce the effect the following morning, typically within 6 to 12 hours.
Preparation	Drops can be mixed with water, milk, or fruit juice. Tablets must be swallowed whole with adequate fluid.
Age-Group Rules	Children aged 4 to 10 years: Daily dose is lower, ranging from 2.5 mg to 5 mg.
Duration	Intended for short-term relief and should not be used for more than five days without medical review.

Instruction Classifications (High-Level)

Classification	Status
Administration Method Type	Oral
Frequency Pattern	Once daily (q.d.)
Use-context Constraints	Short-term use only; Requires adequate fluid intake.

Resulting Procedural Structure

Standard Step Sequence:

A single dose is chosen within the established range and administered orally at bedtime.
The medicine is ingested with sufficient fluid; the drops can be mixed with liquids, but tablets must be swallowed intact.
The dose should be maintained for only short periods.
Once bowel regularity has returned, the dosage must be reduced and discontinued.

Connection to the overall use protocol (2–4 sentences):

The use of sodium picosulfate is structured as a controlled, time-sensitive, and short-term intervention. The regimen is typically taken once daily at night to align the onset of action with the morning hours, thereby ensuring a predictable effect. Furthermore, the protocol involves starting with the lowest dose and gradually reducing its use to support the restoration of natural bowel function.

Recent Clinical Evidence

Research evidence / Overview of studies for Laxoberon

Evidence for Symptomatic Relief of Functional Constipation

The evaluation of Laxoberon, containing Sodium Picosulfate, has primarily focused on the condition of functional constipation, which describes conditions marked by functional limitations and periods of heightened symptoms. The research base consists mainly of Randomized Controlled Trials (RCTs), including double-blind, placebo-controlled designs, which are further analyzed in Systematic Reviews and Meta-analyses by scientific bodies.

In these trials, research examined changes in key outcomes related to physical discomfort and daily functioning. Researchers monitored the change in the number of complete spontaneous bowel movements per week, assessed stool consistency, and tracked patient-reported outcomes describing perceived discomfort, such as straining and bloating. Studies reported measurements that describe patterns observed in the populations during the defined time intervals. This research provides insight into short-term changes and contributes to understanding symptom patterns in conditions characterized by fluctuating manifestations.

Studies Comparing Effectiveness Against Placebo

Clinical research has explored short-term symptom changes by evaluating data associated with Laxoberon against a placebo. These placebo-controlled, double-blind trials were used in research exploring how symptoms change over time. The findings indicate patterns related to the monitored outcomes, such as the number of weekly bowel movements, when compared to the measurements reported by the placebo group.

Some trials were evaluated in research settings that monitored patterns of outcomes reflecting daily functioning and symptomatic patterns, including comparisons against other researched compounds. Evidence quality varies across studies, and the body of comparative evidence remains limited.

Long-Term Evidence and Follow-Up

Studies focusing on episodes where symptoms become more noticeable have typically been conducted over defined, short time intervals. Many of the key randomized controlled trials evaluating Sodium Picosulfate had follow-up durations that were limited, frequently lasting up to four weeks.

Currently, there is limited information for long-term outcomes and the durability of response. The long-term effects of use beyond the four-week period often used in structured trials are not fully established. Research provides context about short-term patterns, but long-term outcomes for extended durations are not fully established.

Overall Strength and What Remains Uncertain

Systematic reviews and major clinical guidance bodies describe the overall research evidence for this class of medicine as having a Moderate evidence level. This classification is based on the consistency of findings measured during the short-term study periods and acknowledges the overall limitations in the evidence landscape.

Research limitations include the continued lack of high-quality data for long-term outcomes. The evidence highlights what is known—that is, the patterns observed in short-term, controlled trials—and what is still uncertain, particularly regarding prolonged use and application across various patient subgroups. Research is ongoing to contribute further to the broader evidence landscape.

Key Studies & References

MHRA Public Assessment Report of over-the-counter stimulant laxatives: benefit-risk review

Frequently Asked Questions (FAQ)

Common questions about Laxoberon (FAQ)

Q: Is Laxoberon the same as the active ingredient Bisacodyl, or is it different?

A: The active ingredient in Laxoberon is Sodium Picosulfate. This substance is a pro-drug that is converted into the active form (BHPM) by bacteria in the colon, where it exerts its effect. According to official documents, both Sodium Picosulfate and Bisacodyl belong to the class of stimulant laxatives that rely on this same active metabolite to produce their effect.

Q: Are there any known interactions between Laxoberon and birth control pills?

A: The official product information advises that accelerated gut transit time can potentially reduce the absorption or effectiveness of other oral medications, including oral contraceptives. Official guidance often indicates that a time separation between taking the laxative and other oral medicines may be necessary.

Q: Does Laxoberon interact with common pain relievers like paracetamol or ibuprofen?

A: Official regulatory information describes a need for caution when the medicine is used alongside certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen. The combination of Sodium Picosulfate with specific NSAIDs may increase the risk of water retention and a related electrolyte imbalance.

Q: What happens if I forget to take a dose of Laxoberon?

A: Regulatory sources for short-term laxatives often describe a pattern where a missed dose may be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose (e.g., the following evening), the regulatory guidance is generally to skip the missed dose to avoid a double dose.

Q: Can Laxoberon cause dependency if used too often?

A: Official warnings state that the long-term overuse of stimulant laxatives, including Sodium Picosulfate, is not recommended. Such excessive use may result in damage to intestinal function, which can potentially lead to chronic constipation.

Q: Is Laxoberon available over-the-counter or does it require a prescription?

A: Sodium Picosulfate preparations are generally regulated to be available for purchase without a prescription (over-the-counter) in pharmacies. However, official restrictions may apply to certain specific combination products or for use in high-risk patient populations.

Q: Can older adults use Laxoberon without special considerations?

A: Official guidance notes that older adults are described as a patient group where particular attention and careful monitoring may be relevant. Regulatory safety information indicates that careful monitoring for signs of fluid or electrolyte imbalance is a risk management consideration for this population.

Q: Do official documents mention any potential interactions with herbal supplements?

A: Official product literature often includes the general precaution that individuals should disclose all medications being taken to their healthcare provider. This general precaution includes all products, such as herbal products, supplements, and vitamins, to properly assess the potential for any drug interactions with the laxative.

Q: Can Laxoberon be used to clear the bowels before a medical procedure?

A: Yes, the active ingredient in Laxoberon, Sodium Picosulfate, is formally indicated for the cleansing of the colon. This use is often specified for preparation before medical procedures, such as a colonoscopy or certain surgeries.

Q: Does the efficacy of Laxoberon decrease over time with repeated use?

A: The medicine is specifically intended for short-term use only and is not intended for continuous use over prolonged periods. Official warnings indicate that long-term, repeated use is associated with a risk of damage to intestinal function, which can lead to chronic constipation.

Q: What does official guidance say about taking Laxoberon if I have liver disease?

A: Official product information for the oral solution (drops) formulation notes that it contains a small amount of alcohol (ethanol). Official guidance describes this factor as a high-risk element that is relevant for individuals who have pre-existing liver disease or conditions like epilepsy.

How should Laxoberon be stored and disposed of?

How to Store and Dispose of Laxoberon

The storage and disposal of Laxoberon (sodium picosulfate) oral solution must strictly follow the conditions defined in regulatory documents to ensure product stability and safety.

Official Storage Requirements

The medicine must be stored below 30 C and kept in a cool dry place. It is a mandatory requirement that Laxoberon be kept out of the sight and reach of children at all times.

Stability and Disposal

The official labeling defines a maximum period of use after the container has been opened. The oral solution must not be used for more than one year (12 months) after the first opening.

To dispose of expired or unused medicine, it must be returned to a pharmacist for proper disposal, as it must not be thrown into household waste or wastewater. Disposal should always align with local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.